Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 6
Mycophenolate mofetil for myasthenia gravis: a clear and present controversy
Authors Heatwole C, Ciafaloni E
Published 5 December 2008 Volume 2008:4(6) Pages 1203—1209
DOI https://doi.org/10.2147/NDT.S3309
Review by Single anonymous peer review
Peer reviewer comments 4
Chad Heatwole, Emma Ciafaloni
Department of Neurology, The University of Rochester, Rochester, New York, USA
Abstract: Mycophenolate mofetil (MMF) has been used to treat myasthenia gravis (MG) for over 10 years. MMF’s use in the MG population stems from its theoretical mechanism of action and the medical literature that supports its benefit in MG patients. Recently, two large, double-blinded, placebo-controlled, randomized clinical trials were initiated to study the effectiveness of MMF for MG. One of these studies found no benefit in taking MMF with 20 mg of prednisone as compared to taking prednisone alone, while the other study demonstrated no advantage in taking MMF against placebo during a 36-week prednisone taper. This article critically reviews the medical literature on MMF’s use in MG and suggests further research avenues on this topic.
Keywords: myasthenia gravis, mycophenolate mofetil, CellCept
© 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.